JEROME B ZELDIS
CIK 1433982 · Executive VP of Research & Dev · last filed 2026-01-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.70M
Companies
8
Total Filings
79
Lifetime Open-Market Net
-$1.48M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PTCT | Director | 22,500 | $75.39 | $1.70M | -$2.00M | 15 | 2026-01-06 |
| NXGLW | Director | 106,664 | $0.02 | $1.6K | $106.6K | 8 | 2025-06-27 |
| SNGX | Director | — | $0.36 | — | $0 | 4 | 2025-06-20 |
| NexImmune, Inc. (NEXI) Delisted | Executive VP of Research & Dev | 235 | $0.00 | $0 | $100.0K | 3 | 2022-04-07 |
| SOLIGENIX, INC. (SNGXW) Delisted | Director | 25,917 | $0.01 | $233 | $12.8K | 9 | 2021-09-24 |
| Streamex Corp. (BSGM) Delisted | Director | 10,794 | $6.35 | $68.5K | $10.5K | 5 | 2020-07-15 |
| Sorrento Therapeutics, Inc. (SRNE) Delisted | See Remarks | 10,000 | $0.00 | $5 | $51.5K | 4 | 2018-11-27 |
| Alliqua BioMedical, Inc. (ALQA) Delisted | Director | 131,125 | — | — | $240.7K | 8 | 2017-07-03 |
Recent Filings · Page 3 of 8
79 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-01-11 | PTCT | Grant (A) | +3,200 | $0 | EDGAR |
| 2022-01-03 | NXGLW | Mixed | +9,091 | $49.9K | EDGAR |
| 2021-09-24 | SOLIGENIX, INC. (SNGXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-18 | SOLIGENIX, INC. (SNGXW) Delisted | Mixed | — | -$37 | EDGAR |
| 2021-03-12 | — | Grant (A) | — | $0 | |
| 2021-02-19 | NexImmune, Inc. (NEXI) Delisted | Buy (P) | +5,882 | $100.0K | EDGAR |
| 2021-02-16 | NexImmune, Inc. (NEXI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-08 | PTCT | Grant (A) | +1,650 | $0 | EDGAR |
| 2020-09-18 | SOLIGENIX, INC. (SNGXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-07-15 | Streamex Corp. (BSGM) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.